May 14, 2020 / 11:34 AM / in 3 months

Indivior profit slumps on legal costs, higher litigation provisions

May 14 (Reuters) - British drugmaker Indivior on Thursday reported a steep fall in first-quarter profit, as it spent heavily on promoting its newer opioid treatment and incurred higher costs related a U.S. investigation into its best-selling drug.

The company, which withdrew its 2020 forecast last month over uncertainty related to the coronavirus crisis, said adjusted operating profit in three months to March fell to $3 million from $102 million a year ago. (

London-listed Indivior, which was spun-off from Reckitt Benckiser, also said it had increased its litigation and antitrust provisions to $621 million from $438 million previously.

Reporting by Pushkala Aripaka in Bengaluru; Editing by Shinjini Ganguli

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below